Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyDiseaseNeuroendocrine CarcinomaPancreatic CancerSubgroupICD10C25.-C80.9MeSHCarcinoma, NeuroendocrinePancreatic NeoplasmsSequenceChemotherapyChemo-substanceCapecitabineTemozolomideChemo-substanceCapecitabineTemozolomideChemo-substanceCapecitabineTemozolomideChemo-substanceCapecitabineTemozolomideNo. Substances2 RadiotherapySupportive therapySupportive substanceCotrimoxazoleDexamethasoneGranisetronSupportive substanceCotrimoxazoleDexamethasoneGranisetronSupportive substanceCotrimoxazoleDexamethasoneGranisetronSupportive substanceCotrimoxazoleDexamethasoneGranisetronNo. Substances3Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlEmetogenicity (ASCO)FatigueNauseaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorStrosberg JRDiseasepankreatisches neuroendokrines Karzinom, ErstlinieOriginDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FloridaProtocols in Revision 1 protocol foundProtocols under revision.Capecitabine 750 / Temozolomide 200, pancreatic neuroendocrine carcinoma (PID1313 V1.1)
